Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 8 5 W ELECTROLYTES.
AMINOSYN II 7% W/ ELECTROLYTES vs TRAVASOL 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Travasol 8.5% with Electrolytes is a parenteral nutrition solution providing amino acids for protein synthesis, electrolytes for maintenance of acid-base balance and osmotic pressure, and calories to prevent protein catabolism and promote anabolism.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
Intravenous infusion via central vein: 500 mL to 2000 mL per day, infused at a rate not exceeding 0.2 g/kg/hour of amino acids. Dosing individualized based on caloric and protein requirements.
None Documented
None Documented
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Variable; amino acids have rapid distribution (minutes) and metabolic elimination (half-life ~1-2 hours for most). Clinical context: continuous infusion maintains steady state; half-life not typically used for dosing but reflects rapid clearance.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Components are eliminated via metabolic pathways (e.g., amino acids undergo deamination, protein synthesis) and renal excretion of waste products (urea, creatinine). 100% of nitrogenous waste is renally excreted; electrolytes are excreted renally proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution